The present disclosure relates to a method for alleviating and/or treating a coronavirus disease in a subject in need thereof, including administering an effective amount of Ganoderma immunomodulatory protein, a recombinant thereof or a fragment thereof to the subject.

The present disclosure relates to a method for alleviating and/or treating a coronavirus disease in a subject in need thereof, including administering an effective amount of Ganoderma immunomodulatory protein, a recombinant thereof or a fragment thereof to the subject.

The inventors surprisingly found that an immunomodulatory protein from Ganoderma can promote neurite outgrowth, suggesting that the immunomodulatory protein from Ganoderma can treat and/or prevent neurological disorders. Accordingly, the invention provides a method for promoting neurite outgrowth, the method comprising exposing the neuron to an effective amount of an immunomodulatory protein derived from Ganoderma, or a recombinant or a composition thereof. The invention also provides a method for treating and/or preventing a neurological disorder, the method comprising administering an effective amount of an immunomodulatory protein derived from Ganoderma, or a recombinant or a composition thereof to a subject.

The inventors surprisingly found that an immunomodulatory protein from Ganoderma can promote neurite outgrowth, suggesting that the immunomodulatory protein from Ganoderma can treat and/or prevent neurological disorders. Accordingly, the invention provides a method for promoting neurite outgrowth, the method comprising exposing the neuron to an effective amount of an immunomodulatory protein derived from Ganoderma, or a recombinant or a composition thereof. The invention also provides a method for treating and/or preventing a neurological disorder, the method comprising administering an effective amount of an immunomodulatory protein derived from Ganoderma, or a recombinant or a composition thereof to a subject.

The present invention relates to a new use of an immunomodulatory protein derived from Ganoderma or a recombinant or a composition thereof in inhibiting cancel stem cells. Particularly, the immunomodulatory protein is derived form Ganoderma microsporum and the cancel stem cell is oral cancer stem cell.

The present invention relates to a new use of an immunomodulatory protein derived from Ganoderma or a recombinant or a composition thereof in inhibiting cancel stem cells. Particularly, the immunomodulatory protein is derived form Ganoderma microsporum and the cancel stem cell is oral cancer stem cell.

The present invention relates to compositions and methods comprising genes and peptides associated with cyclic peptides and cyclic peptide production in mushrooms. In particular, the present invention relates to using genes and proteins from Galerina species encoding peptides specifically relating to amatoxins in addition to proteins involved with processing cyclic peptide toxins. In a preferred embodiment, the present invention also relates to methods for making small peptides and small cyclic peptides including peptides similar to amanitin. Further, the present inventions relate to providing kits for making small peptides.

The present invention relates to compositions and methods comprising genes and peptides associated with cyclic peptides and cyclic peptide production in mushrooms. In particular, the present invention relates to using genes and proteins from Galerina species encoding peptides specifically relating to amatoxins in addition to proteins involved with processing cyclic peptide toxins. In a preferred embodiment, the present invention also relates to methods for making small peptides and small cyclic peptides including peptides similar to amanitin. Further, the present inventions relate to providing kits for making small peptides.

The present disclosure provides a Flammulina velutipes proteoglycan (FPG) and a dual-wavelength screening method and use thereof, and relates to the technical field of biomedicine. In the present disclosure, components such as polysaccharides, proteoglycan (PG), and free proteins in the Flammulina velutipes are extracted through water extraction. The free proteins are removed by protein removal, and the polysaccharides and PG are separated by alcohol precipitation. Sepharose FF ion exchange chromatography and Sephadex G-200 chromatography separation are conducted with water as an eluent. Dual-wavelength detection is conducted to collect an eluate with absorption peaks at both 480 nm and 295 nm wavelengths, such that a componentthe FPG, which has a protein structure and a polysaccharide structure, is retained.

The present disclosure provides a Flammulina velutipes proteoglycan (FPG) and a dual-wavelength screening method and use thereof, and relates to the technical field of biomedicine. In the present disclosure, components such as polysaccharides, proteoglycan (PG), and free proteins in the Flammulina velutipes are extracted through water extraction. The free proteins are removed by protein removal, and the polysaccharides and PG are separated by alcohol precipitation. Sepharose FF ion exchange chromatography and Sephadex G-200 chromatography separation are conducted with water as an eluent. Dual-wavelength detection is conducted to collect an eluate with absorption peaks at both 480 nm and 295 nm wavelengths, such that a componentthe FPG, which has a protein structure and a polysaccharide structure, is retained.